VKTX
Viking Therapeutics Inc
NASDAQ: VKTX · HEALTHCARE · BIOTECHNOLOGY
$30.00
-3.78% today
Updated 2026-05-01
Market cap
$3.63B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$23 – $43
Volume
2.4M
Viking Therapeutics Inc (VKTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-200.00 | $-78235.00 | $-1.59M | $-8.73M | $-11.07M | $-14.76M | $-18.75M | $-24.75M | $-21.78M | $-47.59M | $-48.40M | $-73.38M | $-87.79M | $-278.69M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $22.00 | $3.00 | $6258.00 | $2.60M | $1.79M | $1.45M | $2.61M | $3.74M | $5.82M | $6.10M | $8.67M | $16.75M | $29.71M | $40.82M |
| Free cash flow | $-200.00 | $-78235.00 | $-1.59M | $-8.73M | $-11.07M | $-14.76M | $-18.75M | $-24.75M | $-21.78M | $-47.59M | $-48.40M | $-73.38M | $-87.79M | $-278.69M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $0.00 | $22288.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $12693.00 | $2.31M | $5.91M | $15.79M | $-16.40M | $20.74M | $-2.75M | $10.52M | — | — | — |